Long-Acting Injectable Buprenorphine (LAIB) in Prison: A report on qualitative data from patients who commenced treatment during a clinical trial

Amelia Woods, Catherine Foley, Elizabeth McEntyre, Adrian Dunlop, Bethany White, Nick Lintzeris, Paul Haber, Jillian Roberts & Michael Doyle



Acknowledgements





Background



- Opioid use is common in many CJS
- Opioid Agonist Therapy
 (OAT) ↓ harms
- Access limitations



- Now option for LAIB
 - Widespread use in CJS......



Gap

 Perspectives of participants in CJS

AIM: To explore the perspectives of people currently incarcerated and receiving LAIB



Methods



Study design

- Thematic analysis on open-ended, researcher transcribed face-to-face surveys
- Collected as a part of the UNLOC-T study (up to week 48 following initiation)



Participants

- Recruitment: November 2018 July 2019
- Any LAIB participant from UNLOC-T



Analysis

Open, refined, and axial coding



Results

67 participants

82% male

42% Aboriginal


Median age: 33 (STD 7.51)




5 themes emerged...



























Discussion- Take-away points



Another option

 Retention benefits for some



Tailor treatment to client

Pitfalls and benefits



Discussion-Future Research



Longer term retention- Is it enough to keep people engaged in treatment on release?



Changes with new accessibility (PBS, procedures/policy)

 \rightarrow ? effect on perception



Which cohorts do better, and which do worse? Indications for or against?



Thankyou

